Kymera Therapeutics Inc.

05/20/2022 | Press release | Distributed by Public on 05/20/2022 05:33

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting